Oral LYT-100 (deupirfenidone) was found to be safe and well-tolerated at all doses in an ongoing Phase 1 trial evaluating its potential to treat disorders involving inflammation and fibrosis, such as idiopathic pulmonary fibrosis (IPF), and disorders of lymphatic flow. “Based on these results, we plan to move…
The Three Lakes Foundation, a nonprofit supporting better ways of diagnosing and treating pulmonary fibrosis (PF), announced the release of “Second Wind,” a short documentary film highlighting the need for organ donation. The documentary tells the story of Nick Brown of Indiana and his years of struggle until…
The first patient has enrolled in a clinical trial to understand the effect of Ofev (nindetanib) on adults who developed pulmonary fibrosis (PF) following acute lung injury from COVID-19 infection. “A significant percentage of COVID-19 patients with acute lung injury may develop lung fibrosis based on clinical…
The Pulmonary Fibrosis Foundation (PFF), which supports research that advance understanding and better ways of treating pulmonary fibrosis (PF), is calling for submissions for next year’s PFF Scholars program for emerging scientists. Program winners will receive up to $50,000 over two years for PF research that may ultimately lead…
Leaders in the U.S. rare disease community came together recently for a webinar to present helpful information on how to start a nonprofit and patient registry. They shared about how their respective organizations came to be, as well as the benefits of creating patient registries and how they can help…
A first patient has been enrolled in a proof-of-concept Phase 2 trial of C21 (VP01), Vicore Pharma’s investigational oral therapy for idiopathic pulmonary fibrosis (IPF) and other lung diseases. “We are pleased to announce that we can now start our IPF trial despite the ongoing COVID-19…
The Pulmonary Fibrosis Foundation (PFF) plans to launch “Pinpoint PF,” an educational and awareness campaign for those at risk of pulmonary fibrosis (PF) or showing symptoms, in December. “We introduced the campaign … during the PFF’s virtual Volunteer Meeting and received an enthusiastic response from our PFF Ambassadors…
Newly developed therapies may hold promise for the treatment of pulmonary fibrosis, as described in two studies. The therapies, which are expected to move into clinical trials in the next several months, were both developed by Purdue University scientists in Indiana, led by Philip…
The National Heart, Lung and Blood Institute, part of the National Institutes of Health, has granted $920,000 to a team of researchers at the University at Buffalo (UB) to develop a model that mimics human lung tissue. The researchers say their model should offer an accurate and rapid…
Esbriet (pirfenidone) or Ofev (nintedanib) treatment in adults with idiopathic pulmonary fibrosis (IPF) led to changes in blood markers reflecting reduced systemic inflammation and oxidative stress after 24 weeks of therapy, a small study found. …
Get regular updates to your inbox.
